Other languages Grand Pharmaceutical Group Limited

Equities

512 BMG210A71016

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 am EDT			5-day change	1st Jan Change
4.99 ^HKD	-1.38%		+8.24%	+22.00%

Apr. 29	Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	MT
Mar. 27	Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	Apr. 29
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	Mar. 27
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	Mar. 24
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	Mar. 24
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	Mar. 19
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication	Mar. 08
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial	Mar. 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	Mar. 07
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	Feb. 08
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator	Jan. 24
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	Jan. 16
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	Dec. 27
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	Dec. 27
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	Dec. 22
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan	Dec. 18
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	Dec. 13
Grand Pharmaceutical Unit Enrolls, Doses 1st Patient in Sepsis Drug Phase 2 Trial	Nov. 27
Grand Pharma Gets China's Nod for Phase 1 Clinical Trial for Tumor Vaccine	Nov. 03
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	Nov. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Grand Pharmaceutical Group Limited

Equities

512

BMG210A71016

Other languages

Filters